Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.
Susan Galbraith, MD, PhD
Advertisement
Articles by Susan Galbraith, MD, PhD
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.
Advertisement
Latest Updated Articles
Dr. Galbraith Discusses the Development of AZD9291July 1st 2014
Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLCSeptember 29th 2014
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5